Real-time PCR was performed using an S1000 PCR instrument (Bio-Rad, Hercules, CA, USA) to quantify gene expression
Investigations focus on molecular mechanisms and assay readouts only
GLP-1 receptor agonists and dual GLP-1/GIP co-agonists can produce substantial weight loss, but caloric restriction and weight loss trigger adaptive thermogenesis and neuroendocrine changes (reduced energy expenditure and increased appetite) that facilitate weight regain once therapy is discontinued
Continuous glucose monitoring is helpful because the appetite suppression from semaglutide changes meal timing and size in ways that affect insulin needs
Biosci Biotechnol Res Asia 8(1):259264 Rodthaing T, Kasem S, Khamsuk O, Wongchaochant S, Sukin N, Jompuk P, Chutinanthakun K (2024) Electron beam induced mutation in Curcuma longa L
Clinical Results: Clinical trials have shown that patients using Semaglutide can lose up to 15% of their body weight over 68 weeks when combined with lifestyle changes such as diet and exercise
